Revving Up Dendritic Cells while Braking PD-L1 to Jump-Start the Cancer-Immunity Cycle Motor.
Although it is successful for some, most melanoma patients are refractory to T cell checkpoint inhibition. In this issue of Immunity, Merad and colleagues (2016) describe a dendritic-cell-based strategy to heighten the efficacy of therapeutic anti-PD-L1 and BRAF inhibitors in mouse melanoma models.
Division of Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands.
Seth B
SB
Coffelt
Division of Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands. Electronic address: k.d.visser@nki.nl.
Karin E
KE
de Visser
D000818:Animals; D060890:B7-H1 Antigen; D003713:Dendritic Cells; D006801:Humans; D008545:Melanoma / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology
D060890:B7-H1 Antigen